T-LAK cell-originated protein kinase is essential for the proliferation of hepatocellular carcinoma SMMC-7721 cells

Cell Biochemistry and Function

Volumn 31, Issue 8, 2013, Pages 736-742

  Chen, Fang ^a   Li, Ruwei ^a   Wang, Chenji ^a   Cao, Lihuan ^a   Wang, Yingli ^a   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

AKT; Human hepatocellular carcinoma (HCC); Proliferation; T LAK cell originated protein kinase (TOPK); Tumorigenesis

Indexed keywords

PROTEIN KINASE; SHORT HAIRPIN RNA; T LAK CELL ORIGINATED PROTEIN KINASE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PDZ-BINDING KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

MUS MUSCULUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84897103128     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2964     Document Type: Article

References (31)

1. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140(5): 1410-1426.
2. Kumar M, Zhao X, Wang X. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci 2011; 1(1): 5.
3. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48(6): 2047-2063.
4. Abe Y, Matsumoto S, Kito K, Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem 2000; 275(28): 21525-21531.
5. Gaudet S, Lue RA, Branton D. Characterization of PDZ-binding kinase (PBK), a novel mitotic kinase. Mol Biol Cell 1999; 10: 199a-a.
6. Abe Y, Takeuchi T, Kagawa-Miki L, et al. A mitotic kinase TOPK enhances cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. J Mol Biol 2007; 370(2): 231-245.
7. Nandi A, Tidwell M, Karp JE, Rapoport AP. Regulated expression of PBK/TOPK-a novel mitotic kinase-in acute myelogenous leukemia cells. Blood 2002; 100(11): 200b-b.
8. Dougherty JD, Garcia ADR, Nakano I, et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci 2005; 25(46): 10773-10785.
9. Fujibuchi T, Abe Y, Takeuchi T, et al. Expression and phosphorylation of TOPK during spermatogenesis. Dev Growth Differ 2005; 47(9): 637-644.
10. Qu YX, Adler V, Izotova L, et al. The dual-specificity kinases, TOPK and DYRK1A, are critical for oocyte maturation induced by wild-type but not by oncogenic-ras-p21 protein. Front Biosci 2007; 12: 5089-5097.
11. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006; 66(18): 9186-9195.
12. Oh SM, Zhu F, Cho YY, et al. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. Cancer Res 2007; 67(11): 5186-5194.
13. Nandi AK, Goetzinger KR, Ioffe D, Shapiro PS, Rapoport AP. PBK/TOPK, a novel serine-threonine kinase is up-regulated in hematologic malignancies and upon activation transforms NIH 3T3 cells. Blood 2003; 102(11): 187b-188b.
14. Li S, Zhu F, Zykova T, et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway. J Biol Chem 2011; 286(34): 29601-29609.
15. Park J-H, Nishidate T, Nakamura Y, Katagiri T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci 2009; 101(2): 403-411.
16. Ayllon V, O'Connor R. TOPK promotes tumour cell proliferation through p38MAPK activity and regulation of the DNA damage response. Oncogene 2007; 26(24): 3451-3461.
17. Wei DC, Yeh YC, Hung JJ, et al. Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma. Cancer Sci 2012; 103(4): 731-738. doi:10.1111/j.1349-7006.2011.02197.x.Epub2012Feb3.
18. Shih MC, Chen JY, Wu YC, et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 2012. doi:10.1038/onc.2011.419.
19. Kang NJ, Lee KW, Kim BH, et al. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. Carcinogenesis 2011; 32(6): 921-928.
20. Zykova TA, Zhu F, Vakorina TI, et al. TOPK phosphorylationof Prx1 at Ser32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. J Biol Chem 2010; 285(38): 29138-29146.
21. Fukukawa C, Ueda K, Nishidate T, Katagiri T, Nakamura Y. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer 2010; 49(10): 861-872.
22. Zlobec I, Bihli M, Terracciano L, Lugli A. Diffuse TOPK expression is an adverse prognostic factor in KRAS and BRAF mutated colorectal cancer. Virchows Arch 2009; 455: 47-47.
23. Herrero-Martin D, Osuna D, Ordonez JL, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer 2009; 101(1): 80-90.
24. Zhu F, Zykova TA, Kang BS, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT1 16 colorectal cancer cells. Gastroenterology 2007; 133(1): 219-231.
25. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9(6): 667-676.
26. Crnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16(1): 34-44.
27. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135(6): 1972-1983.
28. Zhou Q, Lui VWY, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011; 7(10): 1149-1167.
29. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129(7): 1261-1274.
30. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279.
31. Moelling K, Schad K, Bosse M, et al. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002; 277(34): 31099-31106.